Additionally, the combination of WNT974 and artesunate (ART) has shown capability in vivo activity by degrading KRAS protein, one of the most challenging oncogenic drivers in colorectal cancer treatment in animals [42]. This evidence concerns the gene KRAS and colorectal cancer.